Cabozantinib efficacy and action description

Cabozantinib is a multi-target tyrosine kinase inhibitor (TKI) that is widely used in cancer treatment. It controls tumor growth, reduces metastasis and improves patient survival by inhibiting multiple key tyrosine kinase receptors, including vascular endothelial growth factor receptor (VEGFR), c-MET receptor and RET receptor. Cabozantinib has a wide range of effects and its indications cover a variety of cancer types, especially showing good efficacy in the treatment of advanced cancer.

Cabozantinib is used as a first-line treatment for patients with advanced renal cell carcinoma (RCC), especially when combined with the immune checkpoint inhibitor nivolumab, it can significantly improve the therapeutic effect. It controls the progression of the disease by inhibiting tumor angiogenesis, reducing tumor blood supply, and reducing tumor cell proliferation. Cabozantinib showed good efficacy in patients with advanced hepatocellular carcinoma who had been treated with sorafenib. It can inhibit the growth of liver cancer cells and effectively delay the spread of tumors.

Cabozantinib can improve patients’ symptoms and prolong their survival by targeting multiple receptors when treating metastatic and progressive medullary thyroid cancer. For DTC patients who have progressed after VEGFR targeted therapy, cabozantinib can effectively delay tumor growth, especially for patients who are ineffective in radioactive iodine therapy, providing a new treatment option.

In summary, cabozantinib, as a multi-target tyrosine kinase inhibitor, can improve the prognosis of patients with advanced cancer through multiple mechanisms, reduce the speed of tumor growth and metastasis, and improve survival rate. Its role in cancer treatment has received increasing clinical attention and provided patients with more treatment options.

Keyword tag:

Cabotinib, Cabozantinib, tyrosine kinase inhibitor, cancer treatment, renal cell carcinoma, medullary thyroid carcinoma, hepatocellular carcinoma, differentiated thyroid cancer, multi-target therapy, cancer efficacy

References:https://actionkidneycancer.org/cabozantinib-most-promising-for-refractory-metastatic-kidney-cancer/